VivoSeq
Immunology

Acute Graft Versus Host Disease

47

Pipeline Programs↗

16

Active Trials↗

30

Companies Involved↗

Acute Graft Versus Host Disease is a moderately active landscape with 47 programs across 30 companies. The most active players are Incyte, Cynata Therapeutics Limited, Salix. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

19/100

Mech. Concentration

14/100

Completion Rate

70/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

2 programs

Phase 1C

Cynata Therapeutics Limited

1 program

Phase 1S

Salix

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 1Pfizer logo

Pfizer

4 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

30 of 45 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody818%Protein / enzyme37%Cell therapy37%Peptide12%

Small molecule leads; the ring shows all 45 classified programs, each share of the total. Modality classified for 100% of 55 pipeline programs.

Analysis

Trial Status

99

clinical trials

Completed47 · 47%
Terminated15 · 15%
Unknown status14 · 14%
Recruiting6 · 6%
Withdrawn5 · 5%
Not yet recruiting5 · 5%
Other7 · 7%

Clinical Trials

Trial Activity

99 trials

Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function
Recruiting·UUniversity of Liege·Phase 2·NCT00603330·100 enrolled
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04744116·24 enrolled
Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05599256·40 enrolled
Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT
Recruiting·—·Phase 2·NCT04118556·50 enrolled
First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 1/2·NCT07285889·35 enrolled
Pilot Trial of Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
Recruiting·CCity of Hope Medical Center·Phase 1·NCT05443425·18 enrolled
Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation
Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06026371·138 enrolled
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Active, not recruiting·Children's Oncology Group·Phase 3·NCT03057054·173 enrolled
Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant
Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04572815·116 enrolled
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease
Active, not recruiting·Mmedac GmbH·Phase 2·NCT06075706·48 enrolled
Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease
Active, not recruiting·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2·NCT04291261·24 enrolled
ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Not yet recruiting·AASC Therapeutics·Phase 2·NCT04883918·60 enrolled
Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease
Not yet recruiting·—·Phase 2·NCT07185633·25 enrolled
Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT06490562·66 enrolled
Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy
Not yet recruiting·RRuijin Hospital·Phase 2·NCT07197112·15 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)